SCHEMBL4669084

SCHEMBL4669084

CN(C)C1(CNc2cccnc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.46
GAA P10253 1/20 0.41
BCDIN3D Q7Z5W3 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADRA2A P08913 2/20 0.40
ADRA2B P18089 2/20 0.40
ADRA2C P18825 2/20 0.40
LATS1 O95835 1/20 0.39
LTA4H P09960 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
NOTUM Q6P988 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4825575 0.98 RAB9A (0.45) RAB9AGAABCDIN3DSMN1; SMN2ADRA2A
SCHEMBL4669443 0.84 SMN1; SMN2 (0.42) RAB9ASMN1; SMN2KDM4ENOTUMALDH1A1
SCHEMBL4669074 0.77 RAB9A (0.46) RAB9AGAABCDIN3DSMN1; SMN2LTA4H
SCHEMBL4670579 0.77 BCDIN3D (0.55) RAB9AGAABCDIN3DADRA2AADRA2B
Hydrochloric Acid SCHEMBL4820587 0.76 RAB9A (0.45) RAB9AGAABCDIN3DADRA2AADRA2B
SCHEMBL4670501 0.76 SMN1; SMN2 (0.45) RAB9AGAASMN1; SMN2LTA4HALDH1A1
Hydrochloric Acid SCHEMBL4826139 0.75 BCDIN3D (0.54) RAB9AGAABCDIN3DADRA2AADRA2B
SCHEMBL4669026 0.73 TNF (0.38) CHRNB2CHRNA4ALDH1A1
SCHEMBL4670889 0.72 CHRNB2 (0.40) KDM4ECHRNB2CHRNA4NOTUMALDH1A1
SCHEMBL3210499 0.71 CHRNA7 (0.51) RAB9AGAASMN1; SMN2LTA4HCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100448848-C New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2009-01-07 CN claimed
EP-1757586-B1 POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG SERVIER LAB (FR) 2008-12-03 EP claimed
US-20080146621-A1 Polysubstituted 1,1-pyridylaminocyclopropanamine compounds LES LABORATORIES SERVIER (FR) 2008-06-19 US claimed
US-7388022-B2 Polysubstituted 1,1-pyridylaminocyclopropanamine compounds LES LABORATOIRES SERVIER (FR) 2008-06-17 US claimed
EP-1757586-A1 POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG Les Laboratoires Servier (FR) 2007-02-28 EP claimed
US-20070027192-A1 Polysubstituted 1,1-pyridylamioncyclopropanamine compounds LES LABORATOIRES SERVIER (FR) 2007-02-01 US claimed
CN-1903844-A New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-01-31 CN claimed
CN-100448848-C New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2009-01-07 CN disclosed
EP-1757586-B1 POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG SERVIER LAB (FR) 2008-12-03 EP disclosed
US-20080146621-A1 Polysubstituted 1,1-pyridylaminocyclopropanamine compounds LES LABORATORIES SERVIER (FR) 2008-06-19 US disclosed
US-7388022-B2 Polysubstituted 1,1-pyridylaminocyclopropanamine compounds LES LABORATOIRES SERVIER (FR) 2008-06-17 US disclosed
EP-1757586-A1 POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG Les Laboratoires Servier (FR) 2007-02-28 EP disclosed
US-20070027192-A1 Polysubstituted 1,1-pyridylamioncyclopropanamine compounds LES LABORATOIRES SERVIER (FR) 2007-02-01 US disclosed
CN-1903844-A New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-01-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146621-A1 Polysubstituted 1,1-pyridylaminocyclopropanamine compounds CHRNA1, CHRM1, CHRNA9 RAB9A 1701/4885GAA 3100/4885BCDIN3D 2620/4885
US-20070027192-A1 Polysubstituted 1,1-pyridylamioncyclopropanamine compounds CHRM1, CHRM2, CHRM3 RAB9A 1492/4885GAA 2858/4885BCDIN3D 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.